ramucirumab,pembrolizumab
eli lilly,merck
['s1800a', 'lung', 'ramucirumab', 'pembrolizumab', 'lillypad']
overall survival from a phase 2 randomized study of ramucirumab plus pembrolizumab vs standard of care for advanced non small cell lung cancer previously treated with immunotherapy: lung-map nonmatched substudy s1800a join in hall d1 at 1 pm. #asco22
Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements